Cargando…
One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy
BACKGROUND: Bone loss during glucocorticoid (GC) therapy is poorly quantified. OBJECTIVE: Quantification of bone loss in GC-treated patients with chronic inflammatory diseases (CID; low dose) and transplants (high dose). METHODS: Meta-analysis of cohorts: PubMed, Cochrane, EMBASE and bibliographic s...
Autores principales: | Lems, Willem F, Baak, Merel M E, van Tuyl, Lilian H D, Lodder, Mariëtte C, Dijkmans, Ben A C, Boers, Maarten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020666/ https://www.ncbi.nlm.nih.gov/pubmed/27651928 http://dx.doi.org/10.1136/rmdopen-2016-000313 |
Ejemplares similares
-
Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease
por: Wiebe, Edgar, et al.
Publicado: (2022) -
Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
por: Saag, Kenneth G., et al.
Publicado: (2019) -
Glucocorticoid-induced osteoporosis
por: Briot, Karine, et al.
Publicado: (2015) -
Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis
por: Theander, Lisa, et al.
Publicado: (2020) -
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses
por: Florez, Helena, et al.
Publicado: (2020)